Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14851 - 14875 of 15222 in total
Experimental
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is a solid. This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.
Experimental
Experimental
An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Experimental
Illicit
Matched Description: … toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and
AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.
Investigational
Matched Description: … consists of slowly dissolving microspheres designed to control where drug particles go in the lung and
5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine is a solid. This compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This drug targets the protein methionine aminopeptidase.
Experimental
Matched Description: … This compound belongs to the benzene and substituted derivatives. …
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and
Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).
Investigational
Matched Description: … Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and
Navocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor/abbv-576 Combination Therapies in Adult Participants With Cystic Fibrosis).
Investigational
Matched Description: … Navocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.[A231859, A231864, A231869] It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M …
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
Matched Description: … in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and
Baxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension).
Investigational
Matched Description: … is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and
KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).).
Investigational
Matched Description: … KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary …
Experimental
Experimental
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
Investigational
Matched Description: … in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and
Displaying drugs 14851 - 14875 of 15222 in total